ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Antibody-drug-conjugate-focused Seattle Genetics is shelling out roughly $614 million in cash to acquire Cascadian Therapeutics, a Seattle-based biotech focused on oncology. The centerpiece of the deal is tucatinib, a HER2 receptor inhibitor currently in Phase II trials as a treatment for people with HER2+ metastatic breast cancer. While two approved drugs, the antibody Herceptin and the antibody-drug conjugate Kadcyla, also target the HER2 receptor, tucatinib is an orally available small molecule, licensed to Cascadian from Array BioPharma.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter